🇺🇸

US SEC Filing Intelligence

· daily

Contract Deobligations Alert — March 12, 2026

This $3.98B batch of 14 contract deobligations is dominated by a $1.7B DOE Hanford cleanup award to Central Plateau Cleanup Co., signaling sustained federal remediation spending; IT modernization contracts for Oracle (VA EHRM, $245M combined), Leidos (DHS, $91M), and Booz Allen (DOJ, $90M) highlight multi-year revenue in healthcare and homeland security IT. Eleven bullish signals outweigh 3 neutrals (nonprofits/small biz), with unexercised options exceeding $800M across deals providing upside; however, 6 contracts show $0 outlays despite multi-year histories, flagging execution delays. Investors should prioritize public federal IT/contractors amid 2026-2033 performance tails.

14 total filings
· daily

Contract Option Exercises — March 12, 2026

Contract option exercises totaling $3.98B signal strong federal spending continuity, dominated by $1.7B DOE Hanford cleanup (Central Plateau) and $817M HHS health exchange outreach (IPG Dxtra), with 11/14 bullish on IT services and construction firms. Multi-year commitments through 2028+ provide revenue visibility for public players like Oracle ($245M VA EHRM), Leidos ($91M DHS), and Booz Allen ($90M DOJ IT), amid zero-outlay delays in 6 contracts. Risks from FFP overruns and T&M audits are offset by $500M+ in unexercised options across deals.

14 total filings
· daily

All HHS Contracts — March 12, 2026

A single massive $817M HHS delivery order to IPG DXTRA, INC. highlights robust federal demand for health insurance exchange outreach via advertising, with $770M already outlayed providing immediate revenue visibility through 2027. This Time & Materials contract under full competition signals strength in government comms services, though long duration exposes to fiscal risks. Investors gain a high-confidence bullish entry on IPG DXTRA and NAICS 541810 peers amid concentrated HHS spending.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — March 12, 2026

Six mega contracts totaling $3.26B signal strong federal spending commitments through 2027, with 5 bullish signals dominated by IT services (Oracle's $245M VA EHRM duo) and remediation services. Unexercised options exceed $167M across contracts, offering upside, while $0 outlays on three awards ($469M total) flag near-term revenue delays. Neutral nonprofit funding to AIT underscores stable but non-equity yielding flows in international affairs.

6 total filings
· daily

High-Value Federal Grants ($5M+) — March 12, 2026

This $3.98B batch of 14 high-value federal contracts (>$5M) signals strong bullish momentum for government contractors in IT modernization, construction, and remediation, with 11/14 rated bullish and total obligations skewed toward DOE ($1.7B Hanford cleanup) and HHS ($817M health exchange outreach). Multi-year performance periods (avg. to 2026-2028) provide revenue visibility, but zero outlays in 6 contracts flag near-term cash flow delays. Institutional investors should prioritize public govcon equities like Oracle, Leidos, and Booz Allen for EHRM, border tech, and FBI IT exposure, while monitoring unexercised options totaling >$700M across deals.

14 total filings
· daily

DOE Energy Grants — March 12, 2026

DOE awarded Central Plateau Cleanup Company a $1.7B cost-plus incentive fee contract for Hanford Central Plateau remediation, with $1.63B outlayed on a 2021-2024 performance period, signaling robust federal spending on nuclear waste management. Unexercised options worth $65.6M and anticipated post-2024 needs offer revenue upside, though execution hinges on 141 subawards totaling $45M. This single large obligation highlights concentration risk in DOE cleanup funding for NAICS 562910 remediation services.

1 total filings
· daily

General Federal Contracts — March 12, 2026

This $3.98B batch of 14 federal contracts shows overwhelming bullish signals (11/14), concentrated in IT services ($1.1B+ across VA Oracle duo, Booz Allen, IBM, others) and construction ($265M+), signaling sustained federal spending on EHR modernization, border enforcement, and infrastructure despite zero outlays in 6 contracts. DOE's $1.7B Hanford cleanup and HHS's $817M health outreach anchor mega-revenue streams through 2027, with DHS (4 contracts, $344M) highlighting border/homeland priorities. Investors should prioritize public IT/construction giants like Oracle and Leidos for revenue visibility, monitoring option exercises ($500M+ potential) amid FFP/T&M execution risks.

14 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 12, 2026

Across 50 diverse SEC filings (despite Consumer Staples focus, spanning tech, biotech, industrials, and media), period-over-period trends reveal mixed revenue performance with 14 companies showing YoY growth >10% (e.g., Angel Studios +233%, SentinelOne +22%, GE Aerospace +18%) versus 16 with declines >10% (e.g., Limoneira -47%, Funko -13.5%, Surf Air -11%), averaging ~ -2% YoY revenue change amid margin pressures (8/20 10-Ks reported EBITDA/margin contraction avg -150bps) but cash flow improvements in 10 cases (e.g., Kodak op cash $480M vs -$7M). Capital allocation leans defensive with buybacks/dividends in 7 firms (e.g., Constellium $300M program, G-III $54M returns) and debt raises/refinancings in 9 (e.g., Keurig $2.55B+$3B notes for JDE Peet’s M&A). Forward-looking data flags 12 catalysts like SentinelOne FY27 rev guide $1.195-1.205B and Surf Air 20-30% 2026 growth, but risks dominate with widening losses in 15 firms (avg +40% YoY) and dilution/delisting threats. Portfolio-level patterns show resilience in services/backlog growth (GE $190B backlog) contrasting consumer weakness; actionable now: favor cash-rich outperformers like GE/Velocity, avoid high-debt loss-makers like Ascend Wellness. Consumer Staples subset (Colgate, Keurig) neutral on board changes/debt for growth.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 12, 2026

Across the 50 SEC filings dated March 12, 2026, for the 'USA S&P 500 Industrials' stream (though spanning diverse sectors), sentiment is mixed in 60% of cases, with revenue trends showing declines in 18/30 reporting companies averaging -6% YoY (e.g., WM Tech -5.3%, Bath & Body Works -0.2%, Stoneridge segments -6-7%), offset by hyper-growth outliers like Abacus Global +110% FY2025 and Angel Studios +233%. Profitability exhibits resilience via turnarounds (Bimini Capital FY NI $5.8M from -$1.3M, Blue Ridge $10.7M from -$15.4M) and margin expansions (Identiv Q4 gross +33pts to 18.1%, National Beverage op income +1.1%). Capital allocation prioritizes returns with 8 instances of dividends/buybacks (Abacus $0.20/share + $20M repurchase, Bimini $2.5M plan) and debt raises for M&A (CACI $500M notes, Longeveron $30M placement). Industrials standouts like GE Aerospace deliver +18% YoY revenue to $45.9B, +38% adj EPS, $190B backlog. Forward guidance is cautious (WM Tech Q1 mid-high single-digit decline seq from Q4 $43.1M), but positive catalysts include Abacus FY26 NI $96-104M and Longeveron ELPIS II readout 3Q26. Risks cluster around asset quality (Pioneer NPA x2 to $11.3M), impairments ($110M Health Catalyst), and restatements (Genie Energy). Implications: Favor selective longs in growth/turnarounds, monitor bank NIM compression and proxy outcomes.

32 high priority 18 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 12, 2026

Across the six S&P 500 Energy stream filings (with some adjacent sectors), overarching themes include YoY revenue and EBITDA growth in energy producers like Hallador Energy (+16% revenue, 3x EBITDA) contrasting with QoQ weaknesses (e.g., Hallador Q4 -30% revenue) and mixed M&A/financing activity; Devon Energy's $TBD Coterra acquisition signals consolidation in oil/gas, while non-core filings highlight executive stability and micro-cap dilutions. Portfolio-level trends show 3/6 companies with YoY revenue surges (Hallador +16-19%, Orchestra +1,169%, Coal +9%) but per-unit pricing declines (Hallador electric -4%, coal -2%) and customer losses, alongside forward-contracted revenues providing visibility ($543-867M through 2029 for Hallador). Critical developments: Hallador's $120M credit facility and Merom gas expansion application bolster growth, Devon's Q2 2026 merger close offers synergies, but regulatory risks (EPA MATS) and dilution loom. Sector implications point to transition plays (coal-to-gas) amid volatility, with positive capital access but execution risks in Q4 results and deals.

5 high priority 1 medium 6 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 12, 2026

Across 50 SEC filings from diverse S&P 500 Financials-linked entities (including banks like Citizens Financial Services, asset managers like AllianceBernstein and Eagle Point, and broader financial services), sentiments are predominantly mixed or neutral, with 12/50 showing positive tilts driven by capital returns and select growth. Period-over-period trends reveal robust NII expansion in financials (e.g., CZFS +13.3% YoY to $99.1M, NIM to 3.50% from 3.13%; Velocity loans UPB +28% YoY to $6.5B, ROE to 17.5%), contrasted by portfolio declines (CION investments -4% to $1.81B, yield to 9.15% from 10.96%) and revenue drops in non-core (ProFrac -11% to $1.94B, Vivid Seats GOV -31% to $2.7B). Capital allocation shines with buyback expansions (Ibotta +$100M to $400M, KLA new $7B program) and dividend hikes (Deutsche Bank to €1.00/share +47%, KLA +21% to $2.30), signaling management conviction amid insider pledges (CZFS directors pledged 14-73% of holdings). Forward-looking data flags Q1 2026 softness (ProFrac EBITDA hit $8-12M weather) but upside catalysts like Gyre's $300M Cullgen acquisition (close Q2 2026) and multiple April AGMs. Portfolio-level, 6/10 financials show NIM/ROE gains vs. sector drags from impairments/losses, implying selective rotation into growing lenders while monitoring buyback-funded returns.

26 high priority 24 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 12, 2026

Across 50 US SEC 8-K filings dated March 12, 2026, dominant themes include widespread board expansions and executive appointments (20+ instances, e.g., healthcare/tech sectors), signaling proactive governance refreshes amid growth ambitions. Capital raising activity is robust with 15+ financings/debt deals totaling >$3B (e.g., CACI $500M notes, NGL $950M term loan, Longeveron $30M PP), extending runways and refinancing maturities, though some mixed with dilution/waivers. M&A completions/ announcements (8 filings, e.g., Laird $38.5M Navitas, T Stamp dual acqs) highlight consolidation in consumer health/tech, while operational distress appears isolated (Vestand closures/resignations). No aggregate YoY/QoQ financial trends due to 8-K focus on events, but capital allocation leans toward debt optimization (10+ refinancings) over dividends/buybacks. Bullish sentiment prevails (60% positive/neutral), with healthcare (Longeveron trial data 3Q26) and fintech leading; bearish outliers in retail/food (Vestand). Implications: Favor liquidity-strong firms pre-earnings; monitor SPACs/mergers for catalysts. Portfolio pattern: Activist settlements (Turtle Beach) and CEO transitions (Build-A-Bear) indicate stabilizing managements.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 12, 2026

Across 21 SEC filings in the USA S&P 500 Technology stream (including adjacent biotech and financials for context), overarching themes include clinical pipeline momentum in biotechs amid persistent cash burns, aggressive capital returns in semiconductors, record revenue growth in software leaders, and M&A consolidation in financials. Period-over-period trends show revenue expansion in Adobe (+12% YoY to $6.40B) and ACNB (+47.1% NII), contrasting sharp declines in Lyell (-41% YoY revenue) and Saga (-5.1% FY revenue), with net losses narrowing in biotechs (Adicet flat at $116.8M, Lyell -20% to $274.4M) but cash positions eroding (Adicet -31% to $38.9M, Lyell -43% to $60.2M). Critical developments feature KLA's 21% dividend hike to $2.30/share and $7B buyback authorization signaling strong conviction, Adobe's AI ARR tripling despite CEO transition, and Esquire-Signature merger at 2.630x exchange ratio. Portfolio-level patterns reveal 4/6 tech filings bullish on capital allocation/growth (KLA, Adobe, ADI, Salesforce ASR), mixed biotech sentiment (2/4 with clinical wins but burns), and neutral proxies. Implications point to selective opportunities in semis/software catalysts, caution on biotech runway, and M&A alpha in consolidations.

12 high priority 9 medium 21 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 12, 2026

Across 21 NASDAQ-100 related filings from March 12, 2026, dominant themes include biotech firms (Adicet Bio, Lyell Immunopharma) reporting flat-to-improved net losses amid clinical advancements and extended cash runways into 2027, contrasted by revenue declines in smaller entities like Liquidmetal (-8.8% YoY) and Saga Communications (-5.1% FY2025). Adobe delivered standout Q1 FY2026 results with 12% YoY revenue growth to $6.40B and reaffirmed FY guidance, though CEO transition introduces uncertainty. Proxy season is in full swing with positive shareholder approvals at Analog Devices (93-99% support) and routine filings for Charter, CHCT, Metallus, and funds, signaling governance stability. Aggregate period trends show mixed revenue performance (3/7 financial reporters grew YoY, avg +4% where positive; 4 declined avg -7%), persistent operating losses in biotechs/healthcare (avg net loss improvement +10% YoY), and capital allocation favoring dividends/buybacks in Saga ($2.5M repurchases) and Metallus ($13.1M). M&A/debt activity via Keurig's $5.55B notes for JDE Peet's acquisition highlights leverage risks, while shelf registrations (Adicet S-3 $250M) flag potential dilution. Portfolio implications favor monitoring biotech catalysts and Adobe momentum, with caution on cash-intensive small caps.

9 high priority 12 medium 21 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 12, 2026

Across 50 SEC filings from diverse US companies (with DJ30 relevance via blue-chips like Salesforce, Colgate-Palmolive, Analog Devices), mixed financial results dominate FY2025/Q1 2026 reporting, with 12/20 10-K/10-Q filings showing revenue growth averaging +25% YoY in outperformers (e.g., Orrstown +110% implied, Abacus +110%) but declines in 8/20 averaging -12% (e.g., Funko -13.5%, LivePerson -22%). Banks/financials (9 filings) exhibit strong balance sheet expansion (avg assets +15%, loans +15%) but NIM compression (-7 bps avg) and rising provisions signal credit stress. Capital allocation leans positive with dividends/buybacks in 6 firms (e.g., Abacus $0.20/share + $20M repurchase) amid $100M+ raises (Longeveron $30M, Kosmos 112M shares). Forward guidance mixed: raises in Abacus ($96-104M), cuts in LivePerson (-15-20% FY26). Resignations/impairments flag risks (Vestand, Health Catalyst $110M goodwill hit), while M&A/litigation (Archer vs Joby, Non Invasive merger) adds volatility. Upcoming April 2026 AGMs (10+ filings) offer voting catalysts; portfolio implication: overweight resilient banks, avoid retail distress.

34 high priority 16 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 12, 2026

Across 50 SEC filings for March 12, 2026, FY2025 results reveal mixed performance with 12/20 10-Ks showing revenue growth averaging +15% YoY (e.g., CZFS NII +13.3%, Velocity loans +28%) but offset by impairments, losses, and margin pressures in 8 cases (avg net loss widening 50%). Capital allocation trends positive in 7 companies with buybacks/dividends totaling >$10B authorized (KLA $7B new, Ibotta +$100M). Healthcare/biotech outliers bullish on trials/acquisitions (Solid Biosciences robust data, Gyre $300M Cullgen deal), while consumer/retail mixed (Build-A-Bear +6.7% rev but guidance decline, Vivid Seats -31% GOV). Proxy season ramps up with 8 April 2026 meetings, neutral sentiment. Energy/financials show NIM expansions (CZFS +37bps, Velocity +26bps YoY) amid pledges/ATM raises signaling caution. Forward guidance cautious with 6 cuts (Gyre rev -4.8-13.8%, Vivid Seats Q1 $570-620M post -42% Q4), but capex disciplined ($155-185M ProFrac). Portfolio implication: Favor capital returners and biotech catalysts over cyclical decliners.

25 high priority 25 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 12, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (retail, automotive, hotels, entertainment, with financial/crypto outliers), sentiment is predominantly mixed (24/50), with positive in 10 and negative in 6; key trends include revenue declines averaging -8% YoY in consumer-facing firms like Funko (-13.5%), Surf Air (-11%), and Lifetime Brands (-5.1%), offset by growth in food/retail like Once Upon a Farm (+53.5% FY sales) and Weis Markets (+3.5%). Crypto ETFs (Grayscale XRP/Solana/Chainlink/Dogecoin, Bitwise ETH) show explosive AUM growth (56-2200% YoY) via share issuances but NAV/share drops 15-40% from unrealized crypto losses. Financials exhibit asset/loan growth (Orrstown +25.7% assets, Citizens NII +13.3%) and NIM expansions (+37bps Citizens), with steady dividends. Forward guidance bullish in select (Once Upon a Farm 25-29% 2026 sales growth, Surf Air 20-30%), but impairments/net losses common (Funko op loss $46M, Braemar hotel net -$13M). Capital allocation leans to dividends/buybacks (Omega Flex div +0.7%, Orrstown accretion), M&A active (Laird Navitas $38.5M). Implications: Tactical buys in growth outliers amid sector caution, watch Q1 2026 catalysts.

37 high priority 13 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 12, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (including cross-sector context from financials and industrials), overarching themes reveal mixed financial performance with robust revenue/asset growth in 12/50 companies (avg +25% YoY where reported, e.g., Orrstown +25.7%, Acacia +133%) offset by margin compression in 8/50 (avg -150bps, e.g., Lennar gross margin 15.2% vs 18.7%) and widening losses in biotechs/financials (e.g., MBX +40% YoY loss). Healthcare-specific highlights include positive clinical catalysts (Solid Biosciences robust Phase 1/2 data, Precision Bio Q4 rev +5600% YoY to $34.2M) amid risks like Stryker's cyber disruption and Cassava's FDA hold. Capital allocation leans defensive with debt retirements (B. Riley $37.9M), repurchases (Lennar $237M, CION $5.2M), and stable dividends (CION $0.36/share), while M&A activity signals consolidation (Esquire-Signature merger at 2.63x exchange). Forward-looking data flags 15+ catalysts into H2 2026, including trial readouts and guidances, positioning selective biotechs for alpha despite sector net losses (9/12 healthcare filers). Portfolio-level trends show improving ROE in outperformers (Velocity +310bps to 17.5%) but rising provisions/NPLs in laggards, urging focus on clinical momentum over broad financials.

28 high priority 22 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 12, 2026

Across 50 filings dated March 12, 2026, focused on US SEC critical events, dominant themes include mixed financial results in biotech/pharma (persistent losses but some expense cuts), explosive AUM growth in crypto trusts offset by NAV declines from crypto price weakness (e.g., Grayscale trusts up 56-229% AUM YoY), and resilient loan/deposit growth in financials/banks (avg +13-25% YoY) amid NIM pressures. Aggregate period trends show revenue growth in 12/20 10-Ks averaging +15% YoY (outliers: Orrstown NII +28.7%, Sonida +23.9%; decliners: CompoSecure -86%, INTEST -12.9%), margin improvements in 7/15 (e.g., Healthpeak NOI +4%, Eastman gross +300bps), but net losses widening in 8/20 due to impairments/debt costs. Capital allocation leans shareholder-friendly with dividend hikes (HKHC +530% to $6.3M, Healthpeak 7% yield) and buybacks implied via cash builds, while M&A catalysts (Laird $38.5M acquisition, NCR Atleos merger consents) signal consolidation. Crypto ETF conversions and SPAC IPOs (Primeage $100M) highlight high-vol opportunities, but resignations (Vestand directors) and proxy equity plan oppositions (Enanta 22% against) flag governance risks. Portfolio implication: Overweight financials/REITs for stability, monitor crypto for ETF catalysts, avoid distressed biotech without pipeline wins.

50 high priority 50 total filings